化合物简介
Pasireotide (SOM230, trade name Signifor) is an orphan drug approved in the U.S. and Europe for the treatment of Cushing's disease and acromegaly in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.
基本信息
中文名称
帕西瑞肽
英文名称
pasireotide
中文别名
英文别名
CAS号
396091-73-9
分子式
C58H66N10O9
分子量
1047.21
精确质量
1046.5
PSA
281.2
LOGP
6.7419
编号系统
UNII
98H1T17066
